Navigation Links
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Date:9/2/2008

a 14-day study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). The study is proceeding as planned. Top-line results from the triple combination study are anticipated to be released in the fourth quarter of 2008.

About Hepatitis C

The hepatitis C virus (HCV) is transmitted primarily through blood or blood products. HCV chronically affects 180 million people worldwide, which makes it over four times more prevalent than HIV. It is a leading cause of cirrhosis, liver cancer and liver failure, despite the fact that many patients can be cured.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol Market 2015-2019 ... insights on the global resorcinol industry. The report highlights the various growth prospects ... scenarios and analysis of primary and secondary inputs from the existing players of ...
(Date:7/31/2015)... HONG KONG , July 31, 2015 ... "Company"), China,s leading provider of ... and stem cell storage services, today announced that the ... with the U.S. Securities and Exchange Commission. The filed ... year ended March 31, 2015. The Form 20-F can ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... detection and quantification of partially hydrolyzed gluten in foods, has been accepted by ... the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” ...
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of ... 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the public ... daily lives. This unique exhibit also features a birthing center for fair goers to ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... , , , ... , , , Transcriptor Reverse ... , , , , ... gene expression profiling experiment. The,improved reliability of commercially available microarray,platforms has shifted the ...
... , , ... , , The following protocol ... research studies,it enables detection of the expression of rare mRNAs in,the ... in normal human coronary arteries, and of,interleukin 6 [IL6] and glycoprotein ...
... , , , ... Over the past decade, many organisms have been the,subject of large-scale genome ... functional analysis. Knowledge of tissues and cells,that express particular genes is key to ... , , , Microarrays and similar high-throughput ...
Cached Biology Technology:Increased Sensitivity in Microarray Analysis 2Increased Sensitivity in Microarray Analysis 3Detection of mRNAs on Cryosections of the,Cardiovascular System Using DIG-Labeled RNA Probes 2Detection of mRNAs on Cryosections of the,Cardiovascular System Using DIG-Labeled RNA Probes 3Detection of mRNAs on Cryosections of the,Cardiovascular System Using DIG-Labeled RNA Probes 4Detection of mRNAs on Cryosections of the,Cardiovascular System Using DIG-Labeled RNA Probes 5Detection of mRNAs on Cryosections of the,Cardiovascular System Using DIG-Labeled RNA Probes 6The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 2The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 3The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 4The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 5The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 6
(Date:7/31/2015)... , Kina, 31. juli 2015 Den ... bliver afholdt af BGI fra den 22. - 25. oktober ... Konferencen fejrer sin 10-års fødselsdag i år. Siden ... mest indflydelsesrige årlige møder på ,omik,-feltet, og er en ... ICG-10 fokuserer på nylige gennembrud og ...
(Date:7/31/2015)... 31 de julio de 2015 BGI llevará a ... ) del 22 al 25 de octubre de 2015, ... La conferencia celebra su décimo aniversario este año. Desde ... una de las reuniones anuales más influyentes del mundo ... de las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... , 31 de julho de 2015 ... www.icg-10.org ) será realizada pela BGI de 22-25 de ... . A conferência está celebrando seu 10 ... 2006, a ICG se tornou uma das reuniões mais ... dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Iowa State University, ConocoPhillips and the U.S. ... have reached a Memorandum of Understanding to identify ... mid- and long-term. The collaboration will bring three ... most efficient and cost-effective methods for making liquid ...
... faculty in the Virginia-Maryland Regional College of Veterinary ... awarded funding from the Wake Forest University Translational ... brain tumors in dogs, cats and humans. ... Department of Small Animal Clinical Sciences (DSACS), is ...
... One of the earliest general anaesthetics to be used by ... thats puzzled doctors for more than 150 years how ... serendipity made by Leeds University PhD student Dr Yahya Bahnasi, ... general anaesthesia and offer the opportunity to design new ...
Cached Biology News:Iowa State, ConocoPhillips and National Renewable Energy Lab to cooperate on biofuels research 2Veterinary college researcher studying brain tumors in people and animals 2Veterinary college researcher studying brain tumors in people and animals 3Chloroform provides clue to 150 year old medical puzzle 2
Green Standard is fluorescein....
... small volume applications, including pediatric, neonatal, geriatric, general adult, veterinary and experimental animals. Automatic Calibration with ... ... ... ...
Human/Mouse/Rat LAR Affinity Purified PAb...
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
Biology Products: